Skip to main navigation Skip to search Skip to main content

A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Project: Other

Project Details

Description

A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Short titleCX‐839‐008
AcronymMisc_Novotech
StatusFinished
Effective start/end date17/07/18 → 5/06/23